Remove 2019 Remove Compounding Remove Insurance
article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025

Pharmacy Times

3 Her program focuses on an appointment-based model and has a cash-based payment model, although they are able to bill some insurances for the visit. May 9, 2019. One study conducted in 2016-2017 found that 10% of new prescriptions for contraceptive pills and patches were written by pharmacists during that period. News release.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Obesity Medication Use Remains Low Among Children | ADA 2025

Drug Topics

1 Researchers conducted a retrospective, observational analysis using data from January 2019 to March 2024. Glucagon Prescribing Not in Full Alignment With ADA Guidelines | ADA 2025 Ashley Gallagher June 25th 2025 Article The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.

article thumbnail

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Pharmacy Times

1,2 Tafamidis in the Treatment of ATTR-CM Initially approved in 2019 3 , tafamidis (Vyndamax; Pfizer) is a selective transthyretin (TTR) kinetic stabilizer that binds to thyroxine-binding sites on TTR tetramers, which prevents dissociation into monomers, or the breakdown into amyloid deposits that damage the heart in ATTR-CM. May 6, 2019.

article thumbnail

Managing Tardive Dyskinesia With VMAT2 Inhibitors in Clinical Practice

Pharmacy Times

Treatment selection is influenced by insurance, cost, and patient-specific factors due to the lack of direct RCT comparisons. 7 Based on a lack of head-to-head randomized clinical trials (RCTs), selection of the most appropriate VMAT2 inhibitor is routinely related to insurance approval, affordability, and patient-specific characteristics.

article thumbnail

Opioid statistics, 2025

The Checkup by Singlecare

Semi-synthetic opioids are scientifically modified versions of these naturally occurring compounds. CDC, 2024) There were more than 125 million opioid prescriptions given to Americans in 2023, a number that’s slowly been decreasing since 2019. ( CDC , 2024) In 2019, 22% of U.S. CDC , 2024) In 2019, 22% of U.S.

FDA
article thumbnail

Mifepristone Reduces HbA1c in Patients With T2D, Hypercortisolism | ADA 2025

Drug Topics

0 Copay Program Effectively Improved Glycemic Control | ADA 2025 Brian Nowosielski June 24th 2025 Article Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana. . $0